99. Chronic intestinal pseudo-obstruction
3 clinical trials,   6 drugs   (DrugBank: 1 drug),   0 gene,   0 pathway

Searched query = "Chronic intestinal pseudo-obstruction", "Chronic idiopathic pseudo-bowel obstruction", "Chronic Idiopathic Intestinal Pseudo-Obstruction", "CIIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04118699
(ClinicalTrials.gov)
December 25, 201923/9/2019Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 TrialEfficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Single Center, Randomized, Placebo Controlled, Double-blind Phase 2 TrialChronic Intestinal Pseudo-obstructionDrug: Rifaximin oral tablet;Drug: Placebo oral tabletYokohama City UniversityASKA Pharmaceutical Co., Ltd.Recruiting20 Years74 YearsAll12Phase 2Japan
2JPRN-jRCT2031190137
25/12/201920/11/2019Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 TrialEfficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial Chronic Intestinal Pseudo-obstruction
CIPO, abdominal bloating
Two tablets of the investigational product per dosing (400 mg of rifaximin) or the placebo are orally administered 3 times daily for 4 weeks.Ohkubo HidenoriNULLRecruiting>= 20age old< 75age oldBoth12Phase 2Japan